Merck (MRK) Says V212 Reduced Incidence of Confirmed HZ Cases in First Phase 3 Trial
Tweet Send to a Friend
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first Phase 3 study results ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
